Therini Bio CEO Mike Quigley (L) and Katerina Akassoglou
Exclusive: Therini raises $36M, will target fibrin protein for Alzheimer's and diabetic macular edema
Therini Bio has raised a $36 million Series A and will head to the clinic with an antibody that neutralizes fibrin, a blood clotting protein …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
